Lexicon Pharmaceuticals (NASDAQ:LXRX) shares are trading higher on Tuesday after the company's SOLOIST and SCORED Phase 3 studies achieved their primary endpoints.
Lexicon Pharmaceuticals is a company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates.
Lexicon Pharmaceuticals shares were trading up 43.02% at $1.84 on Tuesday during the time of publication. The stock has a 52-week high of $5.33 and a 52-week low of $1.03.